Drug Profile
Research programme: age-related cardiovascular and blood disorders therapies - ReCyte Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ReCyte Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ischaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Ischaemia in USA (Parenteral)
- 20 Aug 2015 9182895 - patent info
- 10 Aug 2015 BioTime has a patent protection for the culture of pluripotent stem cells such as embryonic stem cells or induced pluripotent stem cells on positively-charged surfaces